A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancerAlberto Chiappori, M. S. Berger, Marshall T. Schreeder et al.|British Journal of Cancer|2012Cited by 51
A randomized phase II study of carboplatin (C) and etoposide (E) with or without pan-BCL-2 antagonist obatoclax (Ob) in extensive-stage small cell lung cancer (ES-SCLC).Corey J. Langer, M. S. Berger, István Albert et al.|Journal of Clinical Oncology|2011Cited by 19
A phase Ib trial of Bcl-2 inhibitor obatoclax in combination with carboplatin and etoposide for previously untreated patients with extensive-stage small cell lung cancer (ES-SCLC)Alberto Chiappori, M. S. Berger, Marshall T. Schreeder et al.|Journal of Clinical Oncology|2009Cited by 11
Optimizing obatoclax administration schedule: Safety and efficacy of 3-hour versus 24-hour infusion in combination with carboplatin and etoposide for patients with extensive-stage small cell lung cancer (ES-SCLC).Alberto Chiappori, M. S. Berger, Marshall T. Schreeder et al.|Journal of Clinical Oncology|2010Cited by 3
Marked improvement in bone mineral density (BMD) for patients (pts) with monoclonal gammopathy of undetermined significance (MGUS) using zoledronic acid (ZOL)James R. Berenson, R. Swift, Ori Yellin et al.|Journal of Clinical Oncology|2008Cited by 2